Want to join the conversation?
$PFE said it acquired privately-held Bamboo Therapeutics. This acquisition expands $PFE's expertise in gene therapy that complement rare disease portfolio, advanced recombinant Adeno-Associated Virus (rAAV) vector design and production technology, and a fully functional Phase 1/2 gene therapy manufacturing facility.
$BABA seems to be on a roll! But increasing its yearly sales outlook from 48% to 54% seems over-expectation from the company's part, doesn't it?
$JNJ down 2% in pre-market trading. Earnings beat expectations, but sales disappointed. Johnson is cautious on its outlook. How it will perform in the future?
$YHOO is reporting today after market close. Nobody cares about this stock.